Bortezomib 1 mg/mL
| Product Overview | |
| Generic Name | Bortezomib 1 mg/mL |
| Brand Name(s) | Velcade |
| Form | Vial, Lyophilized powder/injection (IV or SC). |
| Strength | 1 mg/mL |
| Therapeutic Class | Antineoplastic (proteasome inhibitor) |
| ATC Code | L01XG01 |
| Manufacturing & Regulatory | |
| Country | Canada, USA, India |
| GMP Compliance | WHO–GMP |
| DMF/CEP | Type II |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 36 months |
| Storage | 20–25 °C |
| Incoterms | Ex-Mexico |
| Lead Time | 7 to 10 days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Not publicly available as parallel traded molecule |
Description
Bortezomib for Injection is an antineoplastic proteasome inhibitor used under specialist oncology supervision for the treatment of multiple myeloma and mantle cell lymphoma. It is supplied as an injectable product, commonly administered by intravenous or subcutaneous route,
